title: A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial.
abstract: OBJECTIVE
  This multicenter phase II study was conducted to investigate the efficacy and safety of carboplatin in combination with paclitaxel administered according to a biweekly schedule as a first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  Eligibility criteria included histologically or cytologically confirmed NSCLC (stage IIIb or IV), no prior treatment, and measurable or evaluable disease. Paclitaxel (140 mg/m(2)) was administered intravenously on day 1, in combination with carboplatin at an area under the concentration time curve (AUC) of 3, every 2 weeks.
  
  
  RESULTS
  Seventy-four patients (45 men) with a median age of 62 years (range 40-74) and a median ECOG performance status of 1 (range 0-2) were enrolled. The response rate was 35.1% [95% confidence interval (CI): 24.4-47.1%], with 26 partial responses. The median survival was 357 days, and the median time to progression was 218 days. Toxicity was generally mild; National Cancer Institute-Common Toxicity Criteria (NCI-CTC) grades 3 and 4 neutropenia was observed in 50.0% of the patients, and grades 3 and 4 nausea/vomiting in 4.1%.
  
  
  CONCLUSIONS
  Biweekly carboplatin combined with paclitaxel demonstrated anti-tumor activity in advanced NSCLC, with response and survival rates similar to those of carboplatin combined with paclitaxel administered every 3 weeks but with a more favorable toxicity profile, and the present data indicate that the regimen is suitable for use on an outpatient basis.
authors.affiliation: Department of Respiratory Medicine, National Hospital Organization Kyushu Medical Center, Chuo-ku, Fukuoka, Japan. ichiki@qmed.hosp.go.jp
authors.forename: Masao
authors.initials: M
authors.lastname: Ichiki
authors.forename: Masayuki
authors.initials: M
authors.lastname: Kawasaki
authors.forename: Koichi
authors.initials: K
authors.lastname: Takayama
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Ninomiya
authors.forename: Mutsuo
authors.initials: M
authors.lastname: Kuba
authors.forename: Fumiyuki
authors.initials: F
authors.lastname: Iwami
authors.forename: Naoki
authors.initials: N
authors.lastname: Miyazaki
authors.forename: Kazunori
authors.initials: K
authors.lastname: Oishi
authors.forename: Sadanori
authors.initials: S
authors.lastname: Takeo
authors.forename: Hisamichi
authors.initials: H
authors.lastname: Aizawa
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Nakanishi
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007564:Japan; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin; D017239:Paclitaxel